News from 2008
Evotec and Boehringer Ingelheim Achieve Milestone in Joint Discovery Collaboration
Evotec AG today announced that a third milestone has been successfully achieved in their collaboration with Boehringer Ingelheim.
Evotec Completes Acquisition of Renovis
Evotec AG announced that the merger has been successfully completed and that Renovis, Inc. is a wholly owned subsidiary of Evotec as of May 5, 2008.
Oxford BioMedica Report Encouraging New Phase II Trial Results with Trovax® in Prostate Cancer
Oxford BioMedica, a leading gene therapy company, announces encouraging new data from its first Phase II trial of TroVax in prostate cancer.
New UK R&D company, Vantia Therapeutics, launched with backing from MVM Life Science Partners, SV Life Sciences and Novo A/S
Vantia Therapeutics, a new UK-based R&D company, has been launched with backing from an investor syndicate led by MVM Life Science Partners, along with SV Life Sciences and Novo A/S.
Oxford BioMedica Announces Data Safety Monitoring Board (DSMB) Recommendation to Continue Trovax® Phase III TRIST Study
Oxford BioMedica announced today that the independent DSMB for the Phase III TRIST study of TroVax in renal cancer has completed its third planned interim analysis and recommended that the study continue without modification.
Clavis Pharma Successfully Completes Clinical Phase I Study in Haematology
Clavis Pharma announced today that an important milestone has been reached in its haematology program with ELACYT™.
Healthcare Brands International Announces the Acquisition of Antula Holdings AB
Healthcare Brands International announces the acquisition of Antula Holdings AB, the privately-owned Scandinavian Over-the-Counter healthcare business, and its subsidiaries.